NCT07187154Recruiting
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
1. Research methods Constructed the "Manual for Graded Management of Postoperative Symptoms of Esophageal Cancer" and developed continuous care Procedures. 2. Randomised controlled studies were conducted to verify the effects of the procedure.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 18 Mar 2023
- Start date
- May 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07187154
What you commit to
- Study type: Interventional
- Planned participants: 300
- From May 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have cognitive impairment or psychiatric illness;
Other
- Refusal to participate
Who the study is looking for
- The patient is aware and able to communicate in Mandarin;
- There are smartphones；
- Proficient in using WeChat mini programs.
- Patients who were scheduled for esophageal cancer resection in participating centers were eligible for inclusion.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.